Russell Investments Group Ltd. boosted its stake in Omnicell, Inc. (NASDAQ:OMCL) by 70.2% during the second quarter, Holdings Channel reports. The fund owned 347,914 shares of the company’s stock after buying an additional 143,474 shares during the period. Russell Investments Group Ltd.’s holdings in Omnicell were worth $14,995,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently modified their holdings of OMCL. Diversified Trust Co purchased a new position in shares of Omnicell during the first quarter valued at approximately $228,000. State of Alaska Department of Revenue increased its position in shares of Omnicell by 3.0% in the first quarter. State of Alaska Department of Revenue now owns 4,080 shares of the company’s stock valued at $165,000 after buying an additional 120 shares during the last quarter. Conestoga Capital Advisors LLC increased its position in shares of Omnicell by 12.9% in the first quarter. Conestoga Capital Advisors LLC now owns 1,513,866 shares of the company’s stock valued at $61,539,000 after buying an additional 172,642 shares during the last quarter. SFE Investment Counsel purchased a new position in shares of Omnicell during the first quarter valued at approximately $332,000. Finally, Legato Capital Management LLC increased its position in shares of Omnicell by 3,965.0% in the first quarter. Legato Capital Management LLC now owns 42,154 shares of the company’s stock valued at $1,037,000 after buying an additional 41,117 shares during the last quarter. 96.35% of the stock is currently owned by institutional investors.
Omnicell, Inc. (NASDAQ OMCL) traded down 2.29% during mid-day trading on Thursday, reaching $49.00. 130,356 shares of the company traded hands. The firm’s market capitalization is $1.84 billion. Omnicell, Inc. has a 12-month low of $30.35 and a 12-month high of $51.98. The company’s 50 day moving average price is $45.01 and its 200 day moving average price is $40.99.
Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, July 27th. The company reported $0.02 EPS for the quarter, meeting the consensus estimate of $0.02. The firm had revenue of $180.90 million for the quarter, compared to analyst estimates of $174.08 million. Omnicell had a positive return on equity of 0.41% and a negative net margin of 1.14%. The business’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.38 earnings per share. Equities research analysts predict that Omnicell, Inc. will post $1.31 EPS for the current year.
WARNING: This story was originally posted by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/2800572/russell-investments-group-ltd-has-15-million-stake-in-omnicell-inc-nasdaqomcl.html.
Several brokerages recently commented on OMCL. BidaskClub downgraded shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $40.00 target price on shares of Omnicell in a research note on Sunday, July 30th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $47.00 target price on shares of Omnicell in a research note on Tuesday, July 25th. Craig Hallum lifted their target price on shares of Omnicell from $46.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, July 28th. Finally, Dougherty & Co lifted their target price on shares of Omnicell from $45.00 to $49.00 and gave the stock a “buy” rating in a research note on Friday, July 28th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Omnicell has a consensus rating of “Buy” and an average price target of $49.00.
In other news, EVP Dan S. Johnston sold 16,400 shares of the firm’s stock in a transaction on Friday, May 19th. The stock was sold at an average price of $40.67, for a total transaction of $666,988.00. Following the transaction, the executive vice president now owns 61,696 shares in the company, valued at $2,509,176.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director James T. Judson sold 12,148 shares of the firm’s stock in a transaction on Friday, May 26th. The shares were sold at an average price of $41.50, for a total value of $504,142.00. Following the transaction, the director now owns 19,130 shares in the company, valued at approximately $793,895. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 199,823 shares of company stock worth $9,301,391. Insiders own 3.77% of the company’s stock.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.